Further evidence showing treatment benefits of beta interferon for MS

October 21, 2004

Results of a European study in this week's issue of THE LANCET provide further evidence that patients with early symptoms of multiple sclerosis given a weekly injection with interferon beta are less likely to progress to full clinical disease after two years follow-up. The study showed that the drug reduced patients' loss of brain tissue compared with individuals given placebo.

Early findings from the ETOMS (early treatment of multiple sclerosis) trial (see Lancet 2001; 357: 1576-82) showed encouraging results for interferon beta in delaying the progression of full clinical symptoms of multiple sclerosis compared with placebo. The same investigators led by Massimo Filippi (Ospedale San Raffaele, Milan, Italy) and colleagues assessed whether this drug can also reduce the rate of patients' brain-volume decrease.

After two years follow up, around a third (31%) of 131 patients given interferon beta and just under half (47%) of 132 patients given placebo converted to clinically definite multiple sclerosis.

The degree of brain-tissue loss assessed by MRI scans was greater among patients given placebo (1.68% loss over the two-year period) compared with individuals given beta interferon (1.18% tissue loss).

Dr Filippi comments: "This study has confirmed in a large cohort of patients at the earliest clinical stage of multiple sclerosis that brain parenchymal loss takes place rapidly, and has shown that 22 mg interferon beta-1a, given subcutaneously once weekly, can alter this process significantly. Whether higher or more frequent doses would enhance or reduce this effect remains untested."

In an accompanying commentary (p 1463), David Miller (Institute of Neurology, London, UK) cautions that it may be premature to conclude that a beneficial effect of interferon beta (or any other treatment) on global brain-atrophy itself will produce a long-term reduction in disability. Nevertheless he concludes: "The report by Filippi and colleagues is encouraging and commends investigators to include brain atrophy as an outcome measure in future trials of potential disease-modifying treatments in multiple sclerosis."
-end-
Contact: Dr Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy;
T) 39-226-433-033;
m.filippi@hsr.it

Professor David H Miller, NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, London WC1N 3BG, UK;
T) 44-207-837-3611;
dmiller@saturn.nmr.ion.ucl.ac.uk

Lancet

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.